Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialys

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. CHYM
4. USO
5. AAPL
6. QCOM
7. IRT
8. ASO
9. LAES
10. PHVS

Go back to Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialys

Ardelyx (ARDX) Director Mott Buys $1M in Stock Following Positive FDA Panel

November 17, 2022 4:14 PM EST

Ardelyx (NASDAQ: ARDX) Director, David Mott, bought 567,000 shares on 11/17/22 at $1.7648.

The value of the purchase was just over $1 million and follows a positive FDA panel vote.

... More

Ardelyx, Inc (ARDX) Stock 'Acting Poorly' Despite 50% Up Move - Citi

November 17, 2022 1:01 PM EST

Citi analyst Yigal Nochomovitz reiterated a Buy rating and $10.00 price target on Ardelyx, Inc (NASDAQ: ARDX), saying with the stock up less than 50% it is acting poorly (only up... More